Home About OPKO Biologics

About OPKO Biologics

Biopharma R&D to Improve Quality of Life

OPKO Biologics is a clinical stage company developing next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs candidates, utilizing CTP, reversible PEGylation and stabilizer-based technologies.

Its state-of-the-art facilities in Israel’s innovative R&D ecosystem houses integrated laboratories, a GLP Bioanalytical unit, CMC development labs and a cGMP certified QC lab, and administrative offices.

Since 2013, OPKO Biologics operates as a wholly-owned subsidiary of  OPKO Health, a diverse healthcare group serving unmet needs with first-class products, comprehensive diagnostics laboratories, robust research and development pipeline and unique pharmaceutical business solutions.

About OPKO Biologics


  • Laura Moschcovich, PhD

    Laura Moschcovich, PhD

    General Manager

    Laura Moschcovich joined OPKO Biologics in 2007 as the Head of Downstream Development, leading the development of the purification process of MOD-4023 (CTP-growth hormone). In 2012 she became a Project Manager responsible for overseeing three different projects in collaboration with different CMOs, taking the responsibility of the technology transfer of the processes developed at OPKO Biologics from development to production. In 2015 she led the CMC activities as Vice President, CMC Operations. Since 2019, Laura has served as General Manager.

    Prior to joining the company, Laura worked at Target-In Ltd., an Israeli startup in partnership with the Hebrew University of Jerusalem, as Head of Downstream Development, where she was responsible for the development of the purification process of an innovative product. Laura completed a post-doctoral fellowship and received her PhD in Biochemistry from Tel Aviv University.

  • Ahuva Bar-Ilan, PhD

    Ahuva Bar-Ilan, PhD

    VP Preclinical and Clinical Pharmacology

    Ahuva joined OPKO Biologics in December 2006 as a senior scientist in the R&D department and led the pharmacology and the bioanalytical studies of the drugs under development. In 2015 she was appointed as the Director of Preclinical and Clinical Pharmacology, responsible for the preclinical proof of concept, pharmacology, and toxicology studies. She is also responsible for clinical pharmacology bioanalytical PK and immunogenicity methods validation and analysis. Prior to joining the company, she was a senior scientist at NatSpears. She completed her PhD in the Biochemistry and Microbiology department at Ben-Gurion University of the Negev in 2001.

  • Sagit Pinto-Finkel, CPA, MBA

    Sagit Pinto-Finkel, CPA, MBA

    VP Finance

    Sagit joined OPKO Biologics in 2014 and was appointed Director of Clinical Finance in 2015, responsible for all financial aspects of the clinical department. She has over two decades of finance and business experience, having held senior positions in pharma, high-tech and communications companies, including multinationals, private companies and publicly traded corporations. Sagit is a CPA, with Bachelor’s Degree in Economics and Accounting from the Hebrew University, Jerusalem and an MBA, with a major in Finance (Cum Laude), from Tel Aviv University.

  • Miri Gerzon-Zakar, M.Sc.

    Miri Gerzon-Zakar, M.Sc.

    Senior Director, CMC

    Miri Gerzon-Zakar joined OPKO Biologics in 2011 as a Research Associate in the Downstream Development department, followed by four years as Head of Downstream Development and Head of Upstream Development for one year. Since 2019, Miri serves as Director of CMC, responsible for production development and manufacturing activities of peptide and protein-based drugs. Miri has extensive experience in drug development, including early and late stage product development, process characterization and validation, tech transfer, regulatory requirements and more. Prior to joining the company, Miri was a project manager in a protein production CMO.  She holds an M.Sc. and B.Sc. in Life Sciences from Ben-Gurion University of the Negev.

  • Dana Avraham, B.Sc, CQE

    Dana Avraham, B.Sc, CQE

    Senior QA Director

    Dana joined the company in December 2015 and in 2020 was appointed Director of Quality. She is responsible for oversight and management of all QA activities, including managing and leading regulatory inspections, assuring product and process quality by establishing and enforcing quality standards, and managing all procedures to ensure all work is carried out according to applicable standards and regulations. Prior to joining OPKO Biologics, she was a Quality Engineer with Omrix Biopharmaceuticals, a Johnson & Johnson company. She holds a B.Sc. in Biotechnology Engineering from the Ben-Gurion University of the Negev; and a Certified Quality Engineer (CQE) certificate from the American Society for Quality (ASQ) and Israel Society for Quality.

  • Gabi Faibish, LLB, MBA

    Gabi Faibish, LLB, MBA

    VP Operations and General Counsel

    Gabi Faibish joined OPKO Biologics in 2015. In 2020 he became the General Counsel, and is responsible for all legal, compliance and privacy matters. In 2022 Gabi was also appointed VP Operations. Gabi has extensive commercial and corporate experience, including international commercial law, privacy, intellectual property protection, labor law and other legal matters. Prior to joining OPKO Biologics, Gabi held several roles in the defense industry.  He holds an LLB from the College of Management; an MBA from the College of Management (with a major in Finance and IT); and a B.A. in Political Science from the Hebrew University of Jerusalem.